WASHINGTON--(BUSINESS WIRE)--Shanghai Sundise Traditional Chinese Medicine Co. Ltd released its multi-center, double-blinded, placebo-controlled clinical phase II trial results at a satellite symposium during the 2013 annual meeting of the American Association for the Study of Liver Diseases (AASLD®). The results indicate that in chronic hepatitis C patients with moderate to severe fibrosis Fuzheng Huayu tablet (FZHY) is safe, well tolerated and tended to stabilize and improve liver fibrosis, making FZHY the first traditional Chinese medicine compound to complete such clinical studies in the treatment of liver diseases.
Help employers find you! Check out all the jobs and post your resume.
